Physician profile
Sima D Powers
NPI 1881070431
$1,520.62
in general payments reported to CMS, 2019-2025
28 companies · $716 in 2025
The $716 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $805 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,520.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $152.62 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
| Janssen Biotech, INC. | $148.62 | 2024-2025 | Rybrevant, Carvykti, Erleada |
| Novartis Pharmaceuticals Corporation | $141.65 | 2024-2025 | |
| Abbvie INC. | $109.57 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $109.26 | 2024-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $91.21 | 2024-2025 | Lynparza, Keytruda |
| Glaxosmithkline, LLC. | $88.36 | 2024-2025 | Ojjaara |
| Astrazeneca Pharmaceuticals LP | $68.79 | 2024-2025 | Imfinzi |
| Adc Therapeutics America, INC. | $61.03 | 2024-2025 | |
| Beigene USA, INC. | $48.55 | 2024 | Brukinsa |
| Boston Scientific Corporation | $40.51 | 2024 | Ranger |
| Sobi, INC | $37.55 | 2024 | |
| Alexion Pharmaceuticals, INC. | $35.69 | 2024-2025 | Ultomiris |
| Genentech USA, INC. | $32.57 | 2024 | Tecentriq, Alecensa, Polivy |
| Pfizer INC. | $32.18 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $29.63 | 2025 | Reblozyl |
| Kyowa Kirin, INC. | $29.28 | 2024 | Poteligeo |
| Incyte Corporation | $29.25 | 2024 | Jakafi |
| Stemline Therapeutics INC. | $28.37 | 2024 | Orserdu |
| Takeda Pharmaceuticals U.S.A., INC. | $27.45 | 2025 | Fruzaqla |
| Daiichi Sankyo INC. | $26.26 | 2024 | Enhertu |
| Kite Pharma, INC. | $26.10 | 2025 | Yescarta |
| Pharmacosmos Therapeutics INC. | $24.60 | 2024 | Cosela |
| Lilly USA, LLC | $23.52 | 2025 | Verzenio, Jaypirca |
| Taiho Oncology, INC. | $22.67 | 2025 | |
| Puma Biotechnology, INC. | $19.46 | 2025 | |
| Exelixis INC. | $18.83 | 2024 | Cabometyx |
| Sumitomo Pharma America, INC. | $17.04 | 2024 | Orgovyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sima Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.